Gumarontinib
Gumarontinib[edit | edit source]
Gumarontinib is a small molecule tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of certain types of non-small cell lung cancer (NSCLC). It is specifically designed to target mutations in the epidermal growth factor receptor (EGFR), which are commonly found in NSCLC patients.
Mechanism of Action[edit | edit source]
Gumarontinib functions by inhibiting the activity of the EGFR tyrosine kinase. EGFR is a transmembrane protein that, when activated by binding to its specific ligands, triggers a cascade of downstream signaling pathways that promote cell proliferation and survival. In many cancers, including NSCLC, mutations in the EGFR gene lead to its constitutive activation, driving uncontrolled cell division and tumor growth. Gumarontinib binds to the ATP-binding site of the mutated EGFR, thereby blocking its kinase activity and inhibiting tumor cell proliferation.
Clinical Use[edit | edit source]
Gumarontinib is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with specific EGFR mutations. These mutations are typically identified through genetic testing of tumor samples. The drug is administered orally and is part of a class of targeted therapies that have improved outcomes for patients with EGFR-mutant NSCLC compared to traditional chemotherapy.
Development and Approval[edit | edit source]
Gumarontinib was developed following the discovery of resistance mechanisms to earlier generations of EGFR inhibitors. It is designed to overcome resistance conferred by the T790M mutation, a common secondary mutation that arises in patients treated with first-generation EGFR inhibitors. The development of Gumarontinib involved extensive preclinical studies and clinical trials to establish its efficacy and safety profile.
Side Effects[edit | edit source]
Common side effects of Gumarontinib include diarrhea, rash, nausea, and fatigue. More serious adverse effects can include interstitial lung disease, liver toxicity, and cardiac effects. Patients receiving Gumarontinib require regular monitoring to manage these potential side effects effectively.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
